Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers
- 1 December 1993
- journal article
- Published by Springer Nature in International Journal of Clinical and Laboratory Research
- Vol. 23 (1-4) , 95-101
- https://doi.org/10.1007/bf02592290
Abstract
We have developed a solid-phase enzyme immunoassay for anti-oxidized low-density lipoprotein antibodies. Most sera showed some degree of non-specific binding to plates coated with oxidized low-density lipoprotein and the autoantibodies to oxidized low-density lipoprotein often appeared to have a relatively low affinity. To differentiate between specific and non-specific binding each sample was tested untreated and after absorption with oxidized low-density lipoprotein. The optical densities obtained with dilutions of the absorbed sample were considered to reflect non-specific binding and were subtracted from values obtained with identical dilutions of the unabsorbed sample, to yield corrected values from which the concentrations of anti-oxidized low-density lipoprotein antibody were calculated. Similar absorptions with native low-density lipoprotein and oxidized human serum albumin failed to induce a significant reduction in binding to immobilized oxidized low-density lipoprotein proving that the antibodies measured by this assay are primarily specific for oxidized low-density lipoprotein. We studied sera from two groups of individuals: (1) 33 subjects submitted to coronary angiography and split into two subgroups depending on the degree of coronary stenosis and (2) 64 healthy individuals also split into two subgroups according to lipid levels. Anti-oxidized low-density lipoprotein antibodies were detected both in patients and healthy individuals. Higher levels were detected in patients with moderate coronary disease and hyperlipemic healthy individuals, but the differences between patients and healthy volunteers or between their respective subgroups did not reach statistical significance. Our results suggest that autoantibodies to oxidized low-density lipoprotein are relatively frequent in both symptomatic and asymptomatic individuals. The investigation of their potential role as a risk factor will require mass screening and long-term follow-up.Keywords
This publication has 27 references indexed in Scilit:
- Erythrocyte-bound low-density lipoprotein immune complexes lead to cholesteryl ester accumulation in human monocyte-derived macrophagesClinical Immunology and Immunopathology, 1991
- Cutaneous xanthoma in association with paraproteinemia in the absence of hyperlipidemia.Journal of Clinical Investigation, 1989
- Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation.The Journal of Experimental Medicine, 1988
- Immunological detection of low-density lipoproteins modified by malondialdehyde in vitro or in vivoBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1987
- Cytotoxic effect of serum on fibroblasts in one case of normolipidemic plane xanthoma and myeloma IgG λAtherosclerosis, 1986
- Lipoprotein-antibody immune complexes their catabolism and role in foam cell formationAtherosclerosis, 1985
- Occurrence of anti-low density lipoprotein antibodies and circulating immune complexes in aged subjectsMechanisms of Ageing and Development, 1985
- Free and complexed anti-lipoprotein antibodies in vascular diseasesAtherosclerosis, 1983
- Studies on the occurrence of circulating immune complexes in vascular diseasesAtherosclerosis, 1978
- Anti‐β‐Lipoprotein Activity of Human Monoclonal ImmunoglobulinsVox Sanguinis, 1972